This study assessed how well glycopeptide therapy is used for patients with febrile neutropenia (FN) linked to hematologic cancers.
A total of 87 patients were examined, revealing that 98% received appropriate glycopeptide treatment, primarily for skin or soft-tissue infections.
The findings indicated that patients with positive cultures had higher mortality rates and suggested glycopeptide therapy should typically be stopped early if no gram-positive infection is found.